Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ionis to purchase 24% stake in Akcea Therapeutics for $500m
Based in Boston of Massachusetts, Akcea Therapeutics is engaged in the development and commercialisation of medicines for the treatment of patients with serious and rare diseases. Under the
Based in Boston of Massachusetts, Akcea Therapeutics is engaged in the development and commercialisation of medicines for the treatment of patients with serious and rare diseases. Under the
Celltrion has initiated enrolment of patients with mild symptoms of SARS-CoV-2 infection and the clinical trial is set to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of
Gilead had already secured EUA status for Veklury for the treatment of patients hospitalised due to severe Covid-19. The expanded EUA status was granted based on data from
Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the U.S. Food and Drug Administration (FDA)
Under the deal, BeiGene will develop, manufacture and commercialise Singlomics’ investigational anti-Covid-19 antibodies, including DXP-593 and DXP-604, across the globe except for Greater China. By using single-cell sequencing
The highly differentiated antibody, HFB30132A, has been rapidly identified, engineered, and evaluated in multiple preclinical studies. A Phase I single-IV administration ascending dose study will assess the safety,
The EC approval enables to use of BLENREP as monotherapy to treat multiple myeloma in adult patients who have secured at least four prior therapies including one proteasome
The Minister of Foreign Affairs of Indonesia, H.E. Retno LP Marsudi and Minister of State Owned-Companies of Indonesia, H.E. Erick Thohir witnessed the signing of the two agreements.
As part of the deal, Acadia has purchased all of the outstanding shares of CerSci for $52.5m in the form of its stock. CerSci shareholders are also eligible
“We are excited to complete our first regulatory submission for CABOMETYX in combination with an immune-checkpoint inhibitor based on the positive results from the CheckMate -9ER phase 3